Core Viewpoint - JD Health (06618) has seen a significant increase in stock price due to rising demand for respiratory disease testing amid the flu season, with a focus on ensuring stable supply and innovative product offerings [1] Group 1: Stock Performance - JD Health's stock rose nearly 4% in early trading, currently up 3.19% at HKD 63, with a trading volume of HKD 149 million [1] Group 2: Market Demand and Response - The demand for flu test kits has surged, leading JD Health to collaborate with brand partners to launch a special supply guarantee mechanism to maintain stable prices [1] - JD Health's medical device department formed an IVD brand alliance with multiple companies to anticipate demand and manage inventory effectively [1] Group 3: Product Innovation - JD Health has launched an exclusive product, Oseltamivir granules (15mg x 18 bags), targeting children's flu treatment by addressing issues of dosage mismatch and medication waste [1] - The new product is designed for a standard 5-day treatment course, simplifying the medication process for parents and significantly reducing drug waste [1] - Since its launch, the product has seen an average daily sales growth rate exceeding 100%, becoming a preferred choice for families preparing for flu season [1]

Core Insights - The demand for respiratory infectious disease testing is rising sharply as flu peaks arrive across various regions, with significant sales growth in flu test kits reported by JD Health [1] - JD Health has established a special guarantee mechanism in collaboration with brand merchants to ensure stable supply without price increases in response to the growing user demand [1] - Multi-detection test kits that can simultaneously test for influenza A, influenza B, COVID-19, and mycoplasma pneumonia have emerged as a new trend this year [1] Group 1 - JD Health has formed an IVD (in vitro diagnostics) brand alliance with multiple test kit brands and manufacturers to predict flu season demand and ensure stable product supply during peak periods [1] - The company has upgraded its fulfillment efficiency, enabling priority receipt and rapid shelving of flu test kits, with some regions able to achieve delivery in as fast as half an hour [1] Group 2 - JD Health offers a comprehensive solution for flu prevention and treatment through its unique "medical-testing-diagnosis-drug" closed-loop service capability, allowing users to consult with doctors online after receiving test results [2] - The company plans to continue monitoring respiratory disease trends and user demand changes, leveraging its supply chain and medical service resources to support early screening and family health management during the flu season [2]

Core Insights - The demand for respiratory infectious disease testing is surging as flu peaks arrive across various regions, with flu test kit sales doubling year-on-year, particularly in Beijing, Tianjin, and Hebei [1][2] - JD Health is leveraging its supply chain advantages to ensure stable supply and prevent price increases, having established a special guarantee mechanism in collaboration with brand merchants [1] - Multi-detection test kits that can simultaneously test for influenza A, influenza B, COVID-19, and mycoplasma pneumonia are emerging as a new trend to meet user needs for rapid diagnosis [1] Supply Chain and Logistics - JD Health has formed an IVD brand alliance with multiple test kit brands and manufacturers to predict flu season demand and ensure stable product supply during peak periods [1] - The company has upgraded its fulfillment efficiency, enabling priority receipt and rapid listing of flu test kits, with some regions like Beijing, Shanghai, Guangzhou, Tianjin, and Shenzhen offering delivery in as fast as 30 minutes [1][2] Healthcare Services - JD Health provides a comprehensive solution for flu prevention and treatment through its unique "medical-testing-diagnosis-drug" closed-loop service, allowing users to consult with doctors online after receiving test results [2] - The company emphasizes its commitment to monitoring respiratory disease trends and user demand, aiming to support early screening and detection for family health management during the flu season [2]

Core Insights - The demand for respiratory infectious disease testing is increasing as flu peaks arrive in various regions [1] - JD Health Medical Devices reported that the sales of flu test kits have doubled in the past week [1] Company Summary - JD Health Medical Devices has seen a significant surge in the sales of flu test kits, indicating a strong market response to the rising demand for testing [1] Industry Summary - The respiratory infectious disease testing market is experiencing heightened activity due to seasonal flu outbreaks, reflecting a broader trend in public health response [1]

Core Viewpoint - JD Health Traditional Chinese Medicine Hospital launched a user care activity "Buy Chinese Medicine, Get a Sweet Treat" to enhance user experience and break the stereotype of traditional Chinese medicine being bitter [1][2] Group 1: User Care Activity - The activity offers users a small treat, such as "Hawthorn strips," with their purchase of Chinese medicine, aiming to alleviate the discomfort of taking medicine and convey a warm service experience [1] - The initiative emphasizes the combination of attentive service and professional medical care, making traditional Chinese medicine more accessible and pleasant for users [1] Group 2: Medical Team and Services - JD Health Traditional Chinese Medicine Hospital covers 29 specialties and has a team of over 7000 clinical Chinese medicine practitioners, including national-level masters and senior doctors [1][2] - The platform provides 24/7 online consultation services with an average response time of just 30 seconds, significantly improving the efficiency and experience of accessing Chinese medicine services [1] Group 3: Supply Chain and Quality Assurance - The hospital has established an efficient nationwide supply chain with over 2300 Chinese medicine SKUs, supporting various forms of medicine such as pills, powders, and decoctions [2] - The delivery rate for orders within 48 hours is as high as 92%, ensuring timely access to medications [2] - The hospital collaborates with quality pharmacies and traditional brands to ensure that all medicinal materials meet pharmacopoeia standards, promoting quality and affordability [2] Group 4: Future Development - JD Health Traditional Chinese Medicine Hospital aims to continue the digitalization, standardization, and humanization of Chinese medicine services, making high-quality resources more accessible to the public [2]

在痛风防治领域，双方将共同探索构建覆盖尿酸监测、用药管理及长期随访的数字化防治体系；在呼吸 与过敏领域，依托专业管线产品，聚焦于构建从预防、诊断到治疗与康复的线上支持体系，让专业健康 服务更加可及；在营养补充领域，双方将整合研发与渠道优势，最终旨在为各年龄段人群提供精准营养 与体重管理解决方案等。 据介绍，随着本次战略合作的达成，金赛药业全球首款长效痛风药物"金蓓欣"伏欣奇拜单抗将在京东健 康开启预约。 此前在11月13日晚间，京东健康发布的2025年第三季度业绩报告显示，期内实现收入171.2亿元，同比 增长28.7%；非国际财务报告准则指标下(Non-IFRS)净利润为19亿元，同比增长42.4%。报告期内，京东 健康全网首发超30款新特药，持续巩固"新特药全网首发第一站"优势。 11月26日，京东健康与金赛药业签署战略合作协议。双方将聚焦儿童健康、痛风、呼吸与过敏、女性健 康、营养补充等六大领域，打造以患者为中心的疾病全周期健康管理解决方案。 官网显示，金赛药业是一家创新驱动的全产业链制药企业。作为长春高新（000661）控股子公司，金赛 药业拥有完整的研产销全产业链体系，年营收超百亿元，已推出核心产品 ...

Summary of JD Health International (6618.HK) Conference Call Company Overview - **Company**: JD Health International (JDH) - **Ticker**: 6618.HK - **Market Cap**: HK$199.5 billion / $25.6 billion - **Industry**: Healthcare Technology Key Takeaways FY25 Guidance - Management reiterated FY25 revenue guidance of **+22% year-over-year** and net profit of **RMB 6.2 billion** [3][19] Recent Trends by Product Category - **Nutrition Products**: Achieved **30%+ year-over-year growth**, contributing significantly to topline growth [4][7] - **Drugs**: Sustained strong momentum with **30%+ year-over-year growth**; expected to continue due to: - Shift in demand from in-hospital to out-of-hospital channels - Increased online penetration as online pharmacies capture user demand [7][8] - **New Drug Launches**: Approximately **30 new drugs** expected to launch on JDH in Q4 2025, similar to previous periods [7] O2O Initiatives - Management views B2C as the core market, with O2O initiatives aimed at fulfilling complete user needs and enhancing supply chain capabilities [8] - **National Medical Insurance Policy**: Currently, JDH has minimal revenue from medical insurance, which is expected to primarily aid traffic growth rather than profit [8] - **Investment in Offline Pharmacies**: JDH invested approximately **RMB 200 million** in offline pharmacies and preposition warehouses for 2025, lower than the initial budget of **RMB 300-400 million** [8] Market Dynamics - The total addressable market (TAM) for out-of-hospital drugs is approximately **RMB 500 billion**, with chronic disease drugs potentially exceeding **RMB 100 billion** [8] - Urgent-use products like cold and fever medicines are expected to account for a smaller share of the market [8] Financial Performance - JDH's revenue for FY23 was **RMB 53.53 billion**, with a projected increase to **RMB 71.50 billion** in FY25 [19][22] - Non-IFRS net profit for FY23 was **RMB 4.14 billion**, expected to rise to **RMB 6.13 billion** in FY25 [19] Risks and Challenges - Key downside risks include: - Slower-than-expected sales growth in 2H25 - Delays in the rollout of medical insurance reimbursement for online orders - Margin pressures due to investments in on-demand delivery initiatives - Increased competition from online pharmacies and O2O peers [21] Price Target and Valuation - **12-Month Target Price**: HK$75 per share, representing an upside of **19.9%** from the current price of HK$62.55 [20][22] Additional Insights - Management emphasized the importance of branding and marketing activities in driving sales growth, particularly in nutrition products [8] - The company is focusing on developing elderly-friendly medical devices to tap into the growing elderly population [8] This summary encapsulates the key points discussed during the conference call, highlighting JD Health's growth prospects, market dynamics, and strategic initiatives.

今年8月份，京东健康与知原药业签署战略合作协议，未来双方聚焦皮肤健康领域，从医药供应链、全 域营销、跨境药品等方面，展开全方位、多维度、深层次的合作。此次与知原药业新品首发的合作，是 双方探索合作的进一步落地。 未来双方还将持续加深合作，合力构建更智能、完善的皮肤全周期健康服务生态，为消费者提供全方位 健康保障。 （编辑 李波） 本报讯 （记者袁传玺）近日，知原药业旗下的丽芙®丙酸氟替卡松乳膏宣布将在京东健康线上首发， 为湿疹、特应性皮炎等皮肤疾病患者提供更加便捷的购药渠道与专业服务。 丙酸氟替卡松乳膏作为一种糖皮质激素类药物，具有抗炎、抗过敏和免疫抑制的多重作用。该药通过抑 制炎症反应，减少炎症介质的释放和炎症细胞的浸润，达到抗炎效果，同时能够有效抑制过敏反应，缓 解患者瘙痒、红肿等过敏性症状。同时，丙酸氟替卡松乳膏适用于成年人及儿童多种皮肤炎症性疾病的 治疗，包括湿疹、特应性皮炎、银屑病等。凭借其抗炎、止痒及快速缓解症状的特点，在全球市场广受 认可。 知原药业是一家专注于皮肤疾病领域创新研发与生产的制药企业，建有国家博士后科研工作站、江苏省 工程研究中心、江苏省企业技术中心、江苏省工程技术研究中心等研发创 ...

Core Insights - Livor Fluticasone Propionate Cream, launched by Zhiyuan Pharmaceutical, will be available on JD Health, providing a convenient purchasing channel and professional services for patients with skin diseases such as eczema and atopic dermatitis [1] Company Overview - Zhiyuan Pharmaceutical specializes in innovative research and production in the field of skin diseases, with established research platforms including a national postdoctoral research station and various engineering research centers in Jiangsu [1] - The company has developed a strong influence in its niche market over more than 20 years of development [1] Product Details - Fluticasone Propionate Cream is a corticosteroid with anti-inflammatory, anti-allergic, and immunosuppressive properties, effective in treating various inflammatory skin diseases in both adults and children [1] - The cream is recognized globally for its ability to suppress inflammation and alleviate allergic symptoms such as itching and redness [1] Strategic Partnership - In August, JD Health and Zhiyuan Pharmaceutical signed a strategic cooperation agreement focusing on skin health, covering areas such as pharmaceutical supply chain, comprehensive marketing, and cross-border pharmaceuticals [1] - The launch of the new product is a further step in the collaboration between the two companies, aiming to enhance their partnership [1] Future Collaboration - The two companies plan to deepen their cooperation to build a more intelligent and comprehensive skin health service ecosystem, providing consumers with all-around health protection [2]

恒指跌2.38%，恒生科技指数跌3.21%，科网、半导体股跌幅靠前，京东健康跌逾8%，中芯国际、华虹 半导体跌逾6%，腾讯音乐、百度集团跌逾5%，阿里巴巴跌逾4%。（AI生成） ...